Tracked worldwide shippingCard and crypto checkoutSealed, lyophilised vialsFor research use only. Not for human or veterinary consumption.Tracked worldwide shippingCard and crypto checkoutSealed, lyophilised vialsFor research use only. Not for human or veterinary consumption.
DBRLABS

Amycretin (Zenagamtide): Trial Results and How It Compares to Eloralintide

Amycretin, now named zenagamtide, is Novo Nordisk’s single molecule acting on GLP-1 and amylin receptors: 24.3% weight loss at 36 weeks in phase 1b/2a, a daily pill version, and phase 3 under way.

Updated 8 November 2026 6 min read 12 primary sourcesHow we research

Key facts

  • Amycretin is Novo Nordisk’s single molecule acting on GLP-1 and amylin receptors (and calcitonin receptors). It has been renamed zenagamtide.[1][2]
  • Weekly injection, phase 1b/2a: 24.3% weight loss at 36 weeks on 60 mg vs 1.1% on placebo.[3]
  • Daily pill, phase 1: 13.1% at 12 weeks on 100 mg vs 1.2% on placebo (exploratory).[4]
  • Phase 3 (AMAZE) started in February 2026, including a head-to-head against semaglutide.[5][6]

What Is Amycretin?

Amycretin, now called zenagamtide, is an investigational Novo Nordisk drug that activates GLP-1, amylin and calcitonin receptors in a single molecule.[1]

Novo’s 2025 annual report refers to it as "zenagamtide (amycretin)". A June 2026 Novo release states "Zenagamtide, also known as amycretin."[2][7] It is being developed both as a once-weekly injection and as a once-daily pill.

Amycretin Weight Loss Results

The once-weekly injection reduced weight by 24.3% at 36 weeks on 60 mg in a phase 1b/2a trial of 125 people, against 1.1% on placebo.[3]

Amycretin injection, weight change vs placebo by dose (phase 1b/2a)
1.25 mg (20 wk)9.7%5 mg (28 wk)16.2%20 mg (36 wk)22%60 mg (36 wk)24.3%

Different treatment lengths per dose: 1.25 mg at 20 weeks, 5 mg at 28 weeks, 20 and 60 mg at 36 weeks. Source: Dahl et al., The Lancet 2025.

  • Oral phase 1 (144 people): 100 mg a day gave 13.1% weight loss at 12 weeks against 1.2% on placebo, with no plateau yet. 62% had adverse events, all mild or moderate.[4][8]
  • Type 2 diabetes, weekly injection, phase 2 (262 adults, 36 weeks): up to 14.6% weight loss on 40 mg against 2.1% on placebo.[7]

Amycretin Phase 3 (AMAZE)

The AMAZE phase 3 programme began on 24 February 2026 with AMAZE 1, a 1,150-person trial of the weekly injection measuring weight change at week 84.[5]

AMAZE 7 tests zenagamtide directly against semaglutide in 650 people.[6] Novo moved both the injection and the pill straight to phase 3 after its 2025 results.[4]

Amycretin vs Eloralintide

Amycretin combines GLP-1 and amylin activity in one molecule, while eloralintide is a pure, selective amylin agonist that Lilly tests alone or alongside tirzepatide.[1][9]

Separate trials; not head-to-head.
FeatureAmycretin (zenagamtide)Eloralintide
DeveloperNovo NordiskEli Lilly
ReceptorsGLP-1, amylin and calcitoninAmylin, selective for AMY1R[10]
FormsWeekly injection and daily pillWeekly injection
Best reported weight result-24.3% at 36 wk (60 mg)[3]-20.1% at 48 wk (9 mg)[11]
Phase 3AMAZE, from Feb 2026ENLIGHTEN, completions from 2028[12]

Lilly’s equivalent of a combined approach is EloraTZP, eloralintide plus tirzepatide, which reached 23.3% at 48 weeks in people with type 2 diabetes. See eloralintide vs tirzepatide.[9]

Frequently Asked Questions

What is amycretin?

An investigational Novo Nordisk drug, now named zenagamtide, that activates GLP-1, amylin and calcitonin receptors in one molecule. It is in phase 3 for weight management.

Is amycretin the same as zenagamtide?

Yes. Novo Nordisk renamed amycretin zenagamtide. Its 2025 annual report and 2026 releases use both names.

How much weight did people lose on amycretin?

Up to 24.3% at 36 weeks on the 60 mg weekly injection in phase 1b/2a, and 13.1% at 12 weeks on the 100 mg daily pill in phase 1.

Is amycretin better than eloralintide?

Its best reported result (24.3% at 36 weeks) is higher than eloralintide’s (20.1% at 48 weeks), but the trials differ and amycretin also acts on GLP-1. No head-to-head trial exists.

Sources

  1. Mora P, et al. Zenagamtide (formerly amycretin) phase 2 in type 2 diabetes. The Lancet 2026;408:621-635
  2. Novo Nordisk Annual Report 2025, 2025 at a glance
  3. Dahl K, et al. Amycretin phase 1b/2a. The Lancet 2025;406:149-162. DOI 10.1016/S0140-6736(25)01185-7
  4. Novo Nordisk press release, 20 Jun 2025: amycretin results and move to phase 3
  5. ClinicalTrials.gov NCT07339423, AMAZE 1 (zenagamtide phase 3)
  6. ClinicalTrials.gov NCT07668414, AMAZE 7 (zenagamtide vs semaglutide)
  7. Novo Nordisk press release, 5 Jun 2026: zenagamtide phase 2 in type 2 diabetes (ADA 2026)
  8. Gasiorek A, et al. Oral amycretin phase 1. The Lancet 2025;406:135-148. DOI 10.1016/S0140-6736(25)01176-6
  9. Eli Lilly press release, 30 Sep 2026: EloraTZP (eloralintide + tirzepatide) phase 2b results
  10. Briere DA, et al. Discovery and first-in-human study of eloralintide. Molecular Metabolism 2025;102:102271. DOI 10.1016/j.molmet.2025.102271
  11. Eli Lilly press release, 6 Nov 2025: eloralintide phase 2 results
  12. ClinicalTrials.gov NCT07321886, ENLIGHTEN-1

For research use only. Not for human or veterinary consumption. This guide summarises published research for information only. It is not medical advice and does not describe any use of products sold on this site.

Related Guides

Basics

What Is Amylin? The Hormone Behind Eloralintide and Cagrilintide

Amylin is a 37-amino-acid hormone released with insulin that slows stomach emptying, curbs glucagon and signals fullness. How amylin analogues work, from pramlintide to eloralintide.

Comparisons

Eloralintide vs Cagrilintide: Two Amylin Analogues Compared

Eloralintide vs cagrilintide: Lilly’s selective amylin agonist vs Novo Nordisk’s non-selective one. Receptor selectivity, half-life, 20.1% vs 10.8% weight loss, CagriSema and amycretin.

Comparisons

Eloralintide vs Semaglutide (Wegovy): Amylin vs GLP-1

Eloralintide vs semaglutide: Lilly’s amylin agonist reached 20.1% weight loss at 48 weeks in phase 2, against 14.9% at 68 weeks for Wegovy in STEP 1. Mechanism, nausea and dosing compared.